Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera.
Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera.
复制标题
评估SARS-COV-2替代病毒中和试验，以检测人，犬，CAT和仓鼠血清中的抗体。
DOI：
10.1128/jcm.02504-20
复制
发表时间：
2021-01-21
影响因子：
9.4
通讯作者：
Peiris M
中科院分区：
文献类型：
--
作者：
Perera RAPM;Ko R;Tsang OTY;Hui DSC;Kwan MYM;Brackman CJ;To EMW;Yen HL;Leung K;Cheng SMS;Chan KH;Chan KCK;Li KC;Saif L;Barrs VR;Wu JT;Sit THC;Poon LLM;Peiris M
需要在没有生物安全3级防护的情况下在多个物种中进行严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的替代中和测定。我们评估了最近开发的替代病毒中和试验（SVNT）相比，90%空斑减少中和试验（PRNT 90）在人，犬，猫和仓鼠血清。以PRNT 90为参考，sVNT的敏感性为98.9%，特异性为98.8%。使用一组对应于其他冠状病毒的免疫血清，我们证实了SARS-CoV-2 sVNT和PRNT 90中缺乏与其他冠状病毒的交叉反应性，除了sVNT中与SARS-CoV-1的交叉反应性。需要在没有生物安全3级防护的情况下在多个物种中进行严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的替代中和测定。我们评估了最近开发的替代病毒中和试验（SVNT）相比，90%空斑减少中和试验（PRNT 90）在人，犬，猫和仓鼠血清。以PRNT 90为参照，sVNT的敏感性为98.9%，特异性为98.8%。使用一组对应于其他冠状病毒的免疫血清，我们证实了SARS-CoV-2 sVNT和PRNT 90中缺乏与其他冠状病毒的交叉反应性，除了sVNT中与SARS-CoV-1的交叉反应性。
Surrogate neutralization assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be done without biosafety level 3 containment and in multiple species are desirable. We evaluate a recently developed surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduction neutralization tests (PRNT90) in human, canine, cat, and hamster sera. With PRNT90 as the reference, sVNT had sensitivity of 98.9% and specificity of 98.8%. Using a panel of immune sera corresponding to other coronaviruses, we confirm the lack of cross-reactivity to other coronaviruses in SARS-CoV-2 sVNT and PRNT90, except for cross-reactivity to SARS-CoV-1 in sVNT. Surrogate neutralization assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be done without biosafety level 3 containment and in multiple species are desirable. We evaluate a recently developed surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduction neutralization tests (PRNT90) in human, canine, cat, and hamster sera. With PRNT90 as the reference, sVNT had sensitivity of 98.9% and specificity of 98.8%. Using a panel of immune sera corresponding to other coronaviruses, we confirm the lack of cross-reactivity to other coronaviruses in SARS-CoV-2 sVNT and PRNT90, except for cross-reactivity to SARS-CoV-1 in sVNT.